Antitumour activity of L-asparaginase and rifampicin.
D000818:Animals; D001215:Asparaginase / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy; D006801:Humans; D007274:Injections, Intraperitoneal; D009052:Leukemia Virus, Murine / Q000472:pathogenicity; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D012316:RNA Nucleotidyltransferases / Q000037:antagonists & inhibitors; D051381:Rats; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012964:Sodium / Q000627:therapeutic use; D014774:Virulence
D001639:Bicarbonates; D012964:Sodium; D012316:RNA Nucleotidyltransferases; D001215:Asparaginase; D012293:Rifampin